Sugi Predict

Sugi Predict / Compounds / SCHEMBL431784

SCHEMBL431784

SCHEMBL431784

Fc1ccccc1-c1cncc(Br)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 5/20 0.51
▸ CYP11B1 P15538 4/20 0.51
▸ CYP2A6 P11509 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ ESR1 P03372 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ TRPA1 O75762 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ CTSA P10619 1/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ PTPRC P08575 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ GRIN1 Q05586 1/20 0.39
▸ GRIN2B Q13224 1/20 0.39
▸ ALOX5AP P20292 1/20 0.39
▸ FEN1 P39748 1/20 0.39
▸ PTK2 Q05397 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20654148 0.86 CYP11B1 (0.63) CYP11B2CYP11B1TRPA1CTSANPC1
SCHEMBL4881 0.83 CYP11B2 (0.44) CYP11B2CYP11B1CYP2A6KDM4EESR1
SCHEMBL5249 0.80 CYP11B2 (0.47) CYP11B2CYP11B1CYP2A6MAPTGRIN2B
SCHEMBL20593949 0.78 PTPRC (0.46) CYP11B2CYP11B1MAPTKMT2ATRPA1
SCHEMBL7396201 0.78 CYP11B1 (0.51) CYP11B2CYP11B1KDM4EMAPTTRPA1
SCHEMBL16702215 0.78 CYP11B1 (0.51) CYP11B2CYP11B1ALOX5APFEN1BACE1
SCHEMBL4771 0.78 CYP2A6 (0.47) CYP2A6KMT2ATRPA1SMN1; SMN2CTSA
SCHEMBL29939240 0.78 CYP11B1 (0.51) CYP11B2CYP11B1ALOX5APFEN1BACE1
SCHEMBL13778292 0.78 CYP11B1 (0.51) CYP11B2CYP11B1CYP2A6MAPTKMT2A
SCHEMBL5109073 0.78 CYP2A6 (0.51) CYP11B2CYP11B1CYP2A6KDM4ETRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2025-09-25 — — US disclosed
US-20230310445-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. 2023-10-05 — — US disclosed
US-20230310445-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. 2023-10-05 — — US disclosed
US-20230310445-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. 2023-10-05 — — US disclosed
EP-4138824-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS Anovia Biosciences, Inc. (US) 2023-03-01 — — EP disclosed
WO-2021216592-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. (US) 2021-10-28 — — WO disclosed
WO-2021216592-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS ANOVIA BIOSCIENCES, INC. (US) 2021-10-28 — — WO disclosed
US-8541404-B2 Inhibitors of the human aldosterone synthase CYP11B2 ELEXOPHARM GMBH (DE) 2013-09-24 — — US disclosed
EP-2280954-B1 6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2 UNIV SAARLAND (DE) 2013-03-27 — — EP disclosed
US-20120022030-A1 Tetracyclic Lactame Derivatives NOVARTIS AG 2012-01-26 — — US disclosed
WO-2009135651-A1 6-PYRIDIN-3-YL-3,4-DIHYDRO-1H-QUINOLIN-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN ALDOSTERONE SYNTHASE CYP11B2 UNIVERSITÄT SAARLANDES (DE) 2009-11-12 — — WO disclosed
US-20090098218-A1 Tetracyclic Lactame Derivatives NOVARTIS AG 2009-04-16 — — US disclosed
US-20090098218-A1 Tetracyclic Lactame Derivatives NOVARTIS AG 2009-04-16 — — US disclosed
US-20090098218-A1 Tetracyclic Lactame Derivatives NOVARTIS AG 2009-04-16 — — US disclosed
WO-2009010488-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS NOVARTIS AG (CH) 2009-01-22 — — WO disclosed
WO-2009010488-A1 HETEROCYCLIC COMPOUNDS USEFUL AS MK2 INHIBITORS NOVARTIS AG (CH) 2009-01-22 — — WO disclosed
US-7442694-B2 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC (US) 2008-10-28 — — US disclosed
EP-1551843-A1 DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS Pfizer Products Inc. (US) 2005-07-13 — — EP disclosed
US-20040106603-A1 Diazabicyclic compounds useful in the treatment of CNS and other disorders PFIZER INC 2004-06-03 — — US disclosed
WO-2004024729-A1 DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS PFIZER PRODUCTS INC. (US) 2004-03-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310445-A1 LOX ENZYME INHIBITING METHODS AND COMPOSITIONS LOX, LOXL1, LOXL2 CYP11B2 677/4885CYP11B1 597/4885CYP2A6 706/4885
US-20250296915-A1 NOVEL AMINO ACID DERIVATIVES DNPEP, BCAT1, ANPEP CYP11B2 4650/4885CYP11B1 4734/4885CYP2A6 4608/4885
US-20120022030-A1 Tetracyclic Lactame Derivatives TNF, RPS6KB2, RPS6KA2 CYP11B2 2079/4885CYP11B1 3178/4885CYP2A6 723/4885
US-20040106603-A1 Diazabicyclic compounds useful in the treatment of CNS and other disorders DBH, CHRNA6, DDT CYP11B2 403/4885CYP11B1 273/4885CYP2A6 240/4885
US-20090098218-A1 Tetracyclic Lactame Derivatives TNF, RPS6KB2, RPS6KA2 CYP11B2 2079/4885CYP11B1 3178/4885CYP2A6 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.